Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11506740 | 0.81 | ALDH1A1 (0.38) | TSHRMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1683063 | 0.80 | ALDH1A1 (0.45) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL5865605 | 0.78 | CYP3A4 (0.38) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9547244 | 0.78 | MAPT (0.41) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9389344 | 0.77 | CYP3A4 (0.37) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL5134780 | 0.77 | MAPT (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL17511614 | 0.77 | CYP3A4 (0.37) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9547338 | 0.76 | — | — | |
| SCHEMBL7252003 | 0.75 | ALDH1A1 (0.41) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9547170 | 0.75 | CYP3A4 (0.33) | CYP3A4TSHRMAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426233-A1 | DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC DISEASES | Mitochon Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | claimed |
| WO-2017155940-A1 | DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC DISEASES | Mitochon Pharmaceuticals, LLC (US) | 2017-09-14 | — | — | WO | claimed |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | claimed |
| EP-3601246-B1 | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS | THE UNIV OF MONTANA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230100940-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022111473-A1 | COMPOUNDS AS MRGPRX2 ANTAGONISTS | BIOARDIS LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11007273-B2 | Prochelators as targeted prodrugs for prostate cancer and methods of making and using same | DUKE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200171160-A1 | PROCHELATORS AS TARGETED PRODRUGS FOR PROSTATE CANCER AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY | 2020-06-04 | — | — | US | disclosed |
| US-20200093831-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-3601246-A1 | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS | The University Of Montana (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10548900-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3426233-A1 | DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC DISEASES | Mitochon Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2019010231-A1 | PROCHELATORS AS TARGETED PRODRUGS FOR PROSTATE CANCER AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2018175418-A1 | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS | THE UNIVERSITY OF MONTANA (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2017155940-A1 | DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC DISEASES | Mitochon Pharmaceuticals, LLC (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093831-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | CYP3A4 1498/4885TSHR 3498/4885MAPT 1834/4885 |
| US-10548900-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | SMN1; SMN2, MYLK2, WFS1 | CYP3A4 1498/4885TSHR 3498/4885MAPT 1834/4885 |
| US-20230100940-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | CYP3A4 1498/4885TSHR 3498/4885MAPT 1834/4885 |
| US-11007273-B2 | Prochelators as targeted prodrugs for prostate cancer and methods of making and using same | FOLH1, FAP, BPHL | CYP3A4 729/4885TSHR 4390/4885MAPT 3553/4885 |
| US-20170252347-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | CYP3A4 1498/4885TSHR 3498/4885MAPT 1834/4885 |
| US-20200171160-A1 | PROCHELATORS AS TARGETED PRODRUGS FOR PROSTATE CANCER AND METHODS OF MAKING AND USING SAME | FOLH1, FAP, BPHL | CYP3A4 729/4885TSHR 4390/4885MAPT 3553/4885 |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | SMN1; SMN2, MYLK2, WFS1 | CYP3A4 1498/4885TSHR 3498/4885MAPT 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.